Results 141 to 150 of about 1,472,050 (256)

Estimating Recent and Historical Effective Population Size of Marine and Freshwater Sticklebacks. [PDF]

Mol Ecol
Feng X, Löytynoja A, Merilä J.
europepmc   +1 more source

Establishment of a humanized patient‐derived xenograft mouse model of high‐grade serous ovarian cancer for preclinical evaluation of combination immunotherapy

Molecular Oncology, EarlyView.
We have established a humanized orthotopic patient‐derived xenograft (Hu‐oPDX) mouse model of high‐grade serous ovarian cancer (HGSOC) that recapitulates human tumor–immune interactions. Using combined anti‐PD‐L1/anti‐CD73 immunotherapy, we demonstrate the model's improved biological relevance and enhanced translational value for preclinical ...
Luka Tandaric, Line Bjørge, Martine Rott Lode, Cecilie Fredvik Torkildsen, Pia Aehnlich, Rammah Elnour, Daniela Elena Costea, Lars Andreas Akslen, Liv Cecilie Vestrheim Thomsen, Emmet McCormack, Katrin Kleinmanns   +10 more
wiley   +1 more source

Multiple merger coalescent inference of effective population size. [PDF]

Philos Trans R Soc Lond B Biol Sci
Zhang J, Palacios JA.
europepmc   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

Dealing With the Complexity of Effective Population Size in Conservation Practice. [PDF]

Evol Appl
Fedorca A, Mergeay J, Akinyele AO, Albayrak T, Biebach I, Brambilla A, Burger PA, Buzan E, Curik I, Gargiulo R, Godoy JA, González-Martínez SC, Grossen C, Heuertz M, Hoban S, Howard-McCombe J, Kachamakova M, Klinga P, Köppä V, Neugebauer E, Paz-Vinas I, Pearman PB, Pérez-Sorribes L, Rinkevich B, Russo IM, Theraroz A, Thomas NE, Westergren M, Winter S, Laikre L, Kopatz A.   +30 more
europepmc   +1 more source

Clinical performance of the urine‐based TERT promoter AbsoluteQ Digital PCR for non‐invasive detection of bladder cancer

Molecular Oncology, EarlyView.
A urine‐based digital PCR assay targeting two hotspot TERT promoter variants detected bladder cancer with high sensitivity and no false positives in this case–control cohort. The streamlined AbsoluteQ workflow outperformed Sanger sequencing and supports non‐invasive molecular testing for bladder cancer detection.
Anna Nykel, Izabela Kubiak, Lena Rutkowska, Żaneta Kasprzyk, Łukasz Kępczyński, Michał Bednarek, Dariusz Sobieraj, Jacek Wilkosz, Piotr Kania, Adam Jędrzejczyk, Bogdan Kałużewski, Agnieszka Gach, Tadeusz Kałużewski   +12 more
wiley   +1 more source

Estimating the Effective Population Size Across Space and Time in the Critically Endangered Western Chimpanzee in Guinea-Bissau: Challenges and Implications for Conservation Management. [PDF]

Evol Appl
da Silva MJF, Borges F, Gerini F, Sá RM, Silva F, Maié T, Hernández-Alonso G, Ramos-Madrigal J, Gopalakrishnan S, Aleixo-Pais I, Djaló SL, Fernandes N, Camará I, Regalla A, Casanova C, Costa M, Colmonero-Costeira I, Rodríguez Fernandes C, Chikhi L, Minhós T, Bruford MW.   +20 more
europepmc   +1 more source

Effective population size in a partially clonal plant is not predicted by the number of genetic individuals. [PDF]

Evol Appl, 2023
Gargiulo R, Waples RS, Grow AK, Shefferson RP, Viruel J, Fay MF, Kull T.   +6 more
europepmc   +1 more source

Estimating Effective Population Size: A Reply to Nunney [PDF]

Evolution, 1995
Brian C, Husband, Spencer C H, Barrett
openaire   +2 more sources

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

Molecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska, Stephany Gallardo, Nur S. Zainal, Leena Arora, Matthew Ellis, Maria‐Antoinette Lopez, Judith Austine, Sai Pittla, Serena J Chee, Aiman Alzetani, Emily C Shaw, Christian H Ottensmeier, Gareth J Thomas, Christopher J Hanley   +13 more
wiley   +1 more source